Quantcast

Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs

May 4, 2011

CRANBURY, N.J., May 4, 2011 /PRNewswire/ — Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced financial results for the first quarter ended March 31, 2011. The Company also highlighted recent and upcoming milestones, including an update on patient enrollment in the ongoing Phase 3 study of its lead program Amigal(TM) (migalastat HCl) for Fabry disease.

Development Pipeline Highlights

  • Enrollment in Phase 3 Amigal study (Study 011) is nearing completion and is expected to be fully enrolled in 2Q11 or 3Q11
  • Phase 2 Amigal extension study continues to provide encouraging safety and renal function data following up to four years of treatment
  • Patient dosing commenced in Phase 2 study of Amigal co-administered with enzyme replacement therapy (ERT) for Fabry disease
  • Moving forward with Phase 2 study of AT2220 (1-deoxynojirimycin HCI) co-administered with ERT for Pompe disease

Matthew R. Patterson, President and Acting Chief Executive Officer of Amicus Therapeutics said, “We continue to make excellent progress across all parts of our business. Our Phase 3 study of Amigal for Fabry disease remains our top priority and we are close to enrolling the final patient. We are also excited to have dosed our first patient in a Phase 2 study evaluating pharmacological chaperones co-administered with ERT. We see this approach as an important extension of our science and a validation of the broader therapeutic potential of our pharmacological chaperone technology. Amicus is in a position of strategic and financial strength due to the positive momentum of our development programs and the successful collaboration with our partner, GSK Rare Diseases. Our team is focused on the achievement of multiple key milestones during 2011.”

First Quarter 2011 Financial Summary

As of March 31, 2011, cash, cash equivalents, and marketable securities totaled $93.8 million, compared to $107.4 million at December 31, 2010.

Total revenue of $6.0 million for the first quarter 2011 consisted of $4.3 million in research revenue and $1.7 million in collaboration revenue, compared to no revenue in the prior year period. Research revenue reflects payments received from GlaxoSmithKline (GSK) for shared development costs of Amigal as part of the Company’s collaboration with GSK. Amicus entered into an agreement with GSK in October 2010 pursuant to which GSK received an exclusive worldwide license to develop, manufacture and commercialize Amigal for the treatment of Fabry disease. Collaboration revenue reflects the recognized portion of the upfront payment received from GSK upon signing the agreement.

Total operating expenses in the first quarter 2011 were $16.0 million, compared to $13.4 million in the prior year period. The increase was primarily attributed to an increase in research and development expenses to $11.1 million in the first quarter from $8.9 million in the prior year period, as a result of contract research and manufacturing costs within the Fabry program.

Net loss attributable to common stockholders for the three months ended March 31, 2011, was $13.4 million, compared to a net loss of $13.2 million for the same period in 2010.

2011 Financial Guidance

Amicus is reiterating previously announced guidance on 2011 operating expenses and the current cash position. The Company expects to spend a total of $45 million to $55 million on 2011 operating expenses, net of cost sharing and milestones related to the GSK collaboration. The current cash position, including anticipated payments from GSK in connection with the collaboration, is expected to be sufficient to fund the Company’s operations and capital expenditure requirements through the anticipated commercial launch of Amigal in the United States.

Upcoming Milestones

Amicus expects to achieve multiple near-term milestones across its three areas of focus: Amigal for the treatment of Fabry disease, pharmacological chaperones co-administered with ERT, and pharmacological chaperones for the treatment of diseases of neurodegeneration. Planned upcoming milestones include the following:

  • Complete enrollment in Study 011, the Phase 3 U.S. registration study of Amigal for Fabry disease, in 2Q11 or 3Q11
  • Begin patient dosing in Study 012, the Phase 3 EU registration study of Amigal for Fabry disease, in 2Q11 or 3Q11
  • Report Phase 2 results for Amigal co-administered with ERT for Fabry disease in 2H11
  • Begin patient dosing in Phase 2 study of AT2220 co-administered with ERT for Pompe disease in 3Q11, with results expected in 1H12
  • Complete late-stage preclinical proof-of-concept studies of AT3375 for Parkinson’s disease, including additional investigational new drug (IND)-enabling activities, in 2H11

Amigal for the Treatment of Fabry Disease

Updated data from an ongoing Phase 2 extension study continue to support the potential of Amigal as an important new treatment option for patients with Fabry disease. Seventeen subjects are receiving treatment in an extension study designed to evaluate the long-term safety and efficacy of Amigal. Preliminary data suggest that Amigal remains generally well tolerated following up to four years of treatment. In patients who have a genetic mutation responsive to Amigal, these data also suggest that treatment may result in maintenance of renal function as measured by estimated glomerular filtration rate (eGFR). In addition, reduced 24-hour urine protein continues to be observed in multiple subjects.

Amicus and GSK are conducting Phase 3 registration studies to support the global approval of Amigal for the treatment of Fabry Disease.

Phase 3 U.S. Registration (Study 011)

Study 011 is a six-month, randomized, double-blind, placebo controlled study of Amigal for Fabry disease. Amicus and GSK are close to achieving target enrollment of 60 patients at 37 centers worldwide. The study is on track to complete enrollment by the end of the second quarter or during the third quarter of this year.

“This Phase 3 study of Amigal is designed to maximize our potential for success, primarily through strict entry criteria,” added Mr. Patterson. “In addition, the latest data from our ongoing Phase 2 extension study continue to demonstrate the potential long-term safety and efficacy of Amigal for Fabry disease. The combination of the data from Phase 2 studies and the robust design of the Phase 3 protocol give us a high degree of confidence in the study.”

Phase 3 EU Registration (Study 012)

Amicus and its partner GSK have opened multiple sites globally for the Phase 3 EU registration study (Study 012) of Amigal for Fabry disease. Patient screening is expected to begin in the second quarter, and dosing of the first patient is anticipated in the second or third quarter of this year. Based on prior interactions with the European Medicines Authority (EMA), Study 012 is designed to be an 18-month, randomized, open-label study comparing the efficacy and safety of Amigal and ERT in male and female patients with Fabry disease who are currently receiving ERT, and who have a genetic mutation responsive to Amigal.

Phase 2 Amigal-ERT Co-Administration Study

In February 2011, Amicus and its partner GSK dosed the first patient in a Phase 2 study evaluating the co-administration of Amigal with ERT for Fabry disease. The announcement of results is on track for the second half of 2011. The open-label Phase 2 study is investigating drug-drug interactions between Amigal and the ERTs Fabrazyme(®) and Replagal(®) in approximately 18 male patients with Fabry disease, ages 18-65, who have been receiving ERT for at least one month before study entry. Two cohorts of nine patients will receive ERT alone and then ERT after a single administration of Amigal at one of two oral dose levels. The primary outcome measure will be safety and a comparison of the ERT activity in plasma, with and without co-administration of Amigal.

AT2220-ERT Co-Administration for the Treatment of Pompe Disease

Amicus has commenced activities for a Phase 2 study of AT2220 co-administered with ERT for Pompe disease. The Company expects to dose the first patient during the third quarter of 2011, and anticipates results in the first half of 2012. The broader use of pharmacological chaperones co-administered with ERT represents an important expansion of the Company’s chaperone technology platform. Preclinical studies have shown that pharmacological chaperones bind to and stabilize the infused ERT, potentially improving its pharmaceutical and pharmacological properties. Preclinical proof-of-concept studies in Fabry and Pompe diseases have demonstrated that a pharmacological chaperone co-administered with ERT can prevent the loss of activity of ERT in the circulation, increase tissue uptake, and increase substrate reduction.

Pharmacological Chaperones for the Treatment of Parkinson’s Disease

Amicus is developing AT3375, its lead pharmacological chaperone targeted at glucocerobrosidase (GCase), as a treatment for Parkinson’s disease. GCase is the enzyme deficient in Gaucher disease, and mutations in the GBA1 gene for GCase are the most common genetic risk factor known for Parkinson’s disease. Gaucher carriers, who have one mutant copy of GCase, are approximately five times more frequent in the Parkinson’s disease population. In addition, Gaucher patients, who have two mutant copies of GCase, have an estimated 20-fold increased risk of developing Parkinson’s disease. AT3375 is expected to advance through late-stage preclinical proof-of-concept studies, including IND-enabling activities, during the second half of 2011.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and webcast today, Wednesday, May 4, 2011, at 5:00 P.M. EDT to review financial results and provide a corporate update. Interested participants and investors may access the conference call at 5 p.m. EDT by dialing 877-303-5859 (U.S./Canada) or 678-224-778 (international).

An audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://www.amicustherapeutics.com, and will be archived for 30 days. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 8 p.m. EDT today. Access numbers for this replay are 800-642-1687 (U.S./Canada) and 706-645-9291 (international); participant code 62822099.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus’ lead program Amigal(TM) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.

About Fabry Disease

Fabry disease is an inherited lysosomal storage disorder that is currently estimated to affect approximately 5,000 to 10,000 people worldwide. Fabry Disease is caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A). The role of alpha-Gal A within the body is to break down a complex lipid called globotriaosylceramide (GL-3). Reduced or absent levels of alpha-Gal A activity leads to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. This accumulation of GL-3 is believed to cause the various symptoms of Fabry disease, including pain, kidney failure, and increased risk of heart attack and stroke.

About Pompe Disease

Pompe disease is an inherited lysosomal storage disorder that affects an estimated 5,000 to 10,000 individuals worldwide and is caused by deficiency in an enzyme called alpha-glucosidase (GAA). Pompe disease is clinically heterogeneous in the age of onset, extent of organ involvement, and rate of progression. The early onset form is most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death between one and two years of age. A high majority of patients develop the late onset form of Pompe disease between childhood and adulthood, which has a slower rate of progression and usually leads to progressive muscle weakness and respiratory insufficiency.

Forward-Looking Statements

This press release contains, and the accompanying conference call will contain, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus’ candidate drug products, the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus’ candidate drug products, and the projected cash position for the Company, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company’s cash position, actual results may differ based on market factors and the Company’s ability to execute its operational and budget plans, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2010. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD-G

Table 1

                            Amicus Therapeutics, Inc.
                          (a development stage company)
                      Consolidated Statements of Operations
                                   (Unaudited)
               (In thousands, except share and per share amounts)

                                                                 Period from
                                                                 February 4,
                                                                     2002
                                                                (inception)
                                            Three Months               to
                                           Ended March 31,          March 31,
                                           ---------------
                                           2010           2011          2011
                                           ----           ----          ----
    Revenue:
       Research revenue                      $-         $4,306       $35,414
       Collaboration revenue                  -          1,660        52,582
                                            ---          -----        ------
    Total revenue                             -          5,966        87,996
                                            ---          -----        ------

    Operating Expenses:
       Research and development           8,889         11,125       225,889
       General and administrative         3,925          4,402        97,771
       Restructuring charges                  -              -         1,522
       Impairment of leasehold
        improvements                          -              -         1,030
       Depreciation and amortization        536            438         8,916
        In-process research and
         development                          -              -           418
                                            ---            ---           ---
    Total operating expenses             13,350         15,965       335,546
                                         ------         ------       -------
    Loss from operations                (13,350)        (9,999)     (247,550)
    Other income (expenses):
       Interest income                       53             59        13,972
       Interest expense                     (83)           (48)       (2,233)
       Change in fair value of
        warrant
           liability                        204         (3,432)       (5,296)
       Other income                           -             70           231
                                            ---            ---           ---
    Loss before tax benefit             (13,176)       (13,350)     (240,876)
    Benefit from income taxes                 -              -         1,834
                                            ---            ---         -----
    Net loss                            (13,176)       (13,350)     (239,042)
       Deemed dividend                        -              -       (19,424)
       Preferred stock accretion              -              -          (802)
                                            ---            ---          ----
    Net loss attributable to
     common stockholders               $(13,176)                   $(259,268)
                                       ========                    =========
                                                      $(13,350)
                                                      ========
    Net loss attributable to
     common   stockholders per
       common share - basic and
        diluted                          $(0.54)        $(0.39)
                                         ======         ======
    Weighted-average common
     shares outstanding -
         basic and diluted           24,289,422     34,498,926
                                     ==========     ==========

SOURCE Amicus Therapeutics


Source: newswire



comments powered by Disqus